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Overall survival (OS) has emerged as the definitive regulatory “be-all, end-all” for the demonstration of benefit in
cancer clinical trials. The reason and the rationale for why this is so are easily appreciated: literally a “test of time,”
OS is a seemingly unambiguous, agenda-free end point, independent of bias-prone variables such as the
frequency and methods of assessment, clinical evaluation, and the definition of progression. However, by general
consensus, OS is an imperfect end point for several reasons: First, it may often be impractical because of the
length, cost, and the size of clinical trials. Second, OS captures the impact of subsequent therapies, both
beneficial (i.e., active) and detrimental, on survival but it does not take into account the contribution of subsequent
therapies by treatment arm; the postprogression period is treated as an unknown black box (no information about
the potential influence of next-line therapies on the outcome) under the implicit assumption that the clinical trial
treatment is the only clinical variable that matters: what OS explicitly measures is the destination, that is, the
elapsed time between the date of randomization (or intention to treat) and the date of death, not the journey, that
is, what transpires in-between.
In long-term maintenance strategies, patients receive treatment in temporally separated but mutually
interdependent and causally linked sequences that exert a “field of influence” akin to action-at-a-distance forces
like gravity, electricity, and magnetism on both the tumor and each other. Hence, in this setting, a new end point,
PFS2, is required to measure this field of influence. This article reviews the definition and use in clinical trials of
PFS2 and makes the case for its potential applicability as a preferred end point to measure the mutual influence of
individual regimens in long-term maintenance strategies with resensitizing agents in particular.
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Clinical trial end points serve different purposes. In conventional
oncology drug development, early-phase clinical trials evaluate safety
and identify evidence of biological drug activity, such as tumor
shrinkage. End points for later-phase efficacy studies commonly
evaluate whether a drug provides a clinical benefit such as
prolongation of survival or an improvement in symptoms. Both the
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) in their respective guidance point out that
confirmatory trials in the evaluation of anticancer medicinal products
should demonstrate that the investigational product provides clinical
benefit. In the Phase 3 studies conducted, there should thus besufficient evidence available demonstrating that the chosen primary
end point can provide a valid and reliable measure of clinical benefit
in the patient population described by the inclusion criteria.
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and progression- or disease-free survival (PFS/DFS). The choice of
primary end point should be guided by the relative toxicity of the
experimental therapy, but parameters such as expected survival after
progression, available next-line therapies, and the prevalence of the
conditionmust also be taken into account. Irrespective of chosen primary
end point, it is the magnitude of the treatment effect on all relevant
outcome measures that forms the basis of the benefit–risk assessment.
If PFS/DFS is the selected primary end point, OS should typically
be reported as a secondary end point and vice versa. Convincingly
demonstrated favorable effects on OS are from both a clinical and
methodological perspective the most persuasive outcome of a clinical
trial. Although prolonged PFS/DFS is in most cases considered a
relevant measure of patients benefit, the magnitude of the treatment
effect would need to be sufficiently large to outbalance toxicity and
tolerability problems. To capture possible negative effects on the
activity of next-line therapies and also treatment-related fatalities,
informative data on OS compatible with a trend toward favorable
outcome are normally expected at time of submission.
If life is a journey, then the destination is represented by OS, a
black box measurement of the time elapsed from a particular point A
to point D (death) where what happens between A and D is irrelevant
for measurement. For this reason, the end point is susceptible to
confounding by subsequent treatments. Nevertheless, by tradition
and by default, OS is universally regarded as the most clinically
compelling end point in clinical trials, provided quality of life is not
adversely affected. Simple to measure and easy to interpret (date of
death is ostensibly bias-free), FDA director Richard Pazdur refers to it
as “the gold standard” [1].
The FDA’s preference for it notwithstanding, OS, by general
consensus, is onerous, expensive, and impractical [2] because it may
take years for survival data to mature; this is particularly the case for
trials that involve either maintenance therapy strategies or indolent,
slow-growing tumors, for example, prostate cancer, where the time on
trial itself may be prohibitively long. On the premise that oncology as
a whole benefits from faster, shorter, and smaller trials, and “proof of”
as soon as possible, consequently increasing treatment options for
patients, various end points have been proposed and selected as
surrogate end points for OS, including PFS.
The primary advantage of the PFS end point, defined as time from
randomization until first evidence of tumor progression or until death
from any cause, whichever comes first [3,4], also constitutes a major
drawback: because progression, in most cases, is an event that occurs
months or years before death, PFS is reached sooner than OS;
however, a short-term indication of benefit is not necessarily an
indication of long-term impact and/or benefit especially if the
experimental treatment induces tumor resistance to subsequent radio-
and chemotherapies. Conversely, a short PFS does not necessarily
predict a poor OS if exposure to the experimental treatment sensitizes
the tumors to the effect of subsequent radio- or chemotherapies.
Indeed, PFS ultimately correlates poorly with OS in the majority of
cancers [3], likely because it only measures clinical benefit on-therapy,
not off-therapy, and because of the possibility that patients receive
subsequent anticancer therapies in a nonrandomized and nonstrati-
fied manner with potentially unequal or undetermined effects on
patient survival, potentially “washing out” a real survival benefit from
the experimental therapy.
In addition, PFS, as an imaging-oriented end point, even with
independent review and adjudication, may be prone to measurementbias and variation in interpretation, leading to possible treatment
discontinuation if progression is not subsequently verified—this is
especially evident in the context of pseudoresponse (apparent
response without a true cytotoxic effect) and pseudoprogression [5]
(apparent radiological progression without clinical deterioration).
Pseudoresponse occurs with bevacizumab in gliomas because of
vascular normalization, whereas pseudoprogression, where tumor size
increases because of treatment-related necrosis and edema, is a
common complication with imatinib (Gleevec) in gastrointestinal
stromal tumors [6] and with radiotherapy and temozolomide in brain
neoplasms. In the case of immunotherapies like the anti–PD-1 and
anti–PDL-1 antibodies, as well as the anticytotoxic T-lymphocyte
antigen–4 antibody ipilimumab, PFS may also be difficult to interpret
as a result of immunologic responses and pseudoprogression [7].
To address these limitations and thereby improve the clarity of the
cloudy PFS crystal ball, a recent EMA guidance recommends a
substitute end point intermediate to PFS and OS called PFS2, a
surrogate for OS when OS cannot be measured (for clinical or
financial reasons), which assesses the impact of the experimental
therapy on next-line treatment. PFS2, which could be termed PFS
deferred, PFS delayed, tandem PFS, or PFS version 2.0, is defined in
the EMA guidance as “time from randomisation to objective tumour
progression on next-line treatment or death from any cause. In some
cases, time on next-line therapy may be used as proxy for PFS.” [8].
For clarity, PFS2 does not refer to the 2-month time point, which
distinguishes it from PFS at 6 months (PFS6), PFS at 12 months
(PFS12), and PFS at 24 months (PFS24).
This lack of correlation between OS and PFS in most, but not all,
tumor types, with ovarian cancer and colorectal cancer as the only
exceptions [3] (although biostatisticians [9] and the regulators at the
FDA and EMA who depend on their recommendations do not
encourage reliance on PFS to assess novel therapies even in these
tumor types), may be related to the omnipresent specter of resistance,
described by Gatenby [10] and others [11], which invariably develops
in response to the selective pressure of treatment. Resistance is an
incremental process; each line of therapy not only selects for
mutations but also triggers a reparative response [12,13] that reduces
treatment susceptibility, resulting in a progressive “dilution” of the
PFS effect. The end result is a highly resistant tumor with a legacy of
multiple coexisting, resistance-conferring mutations.
In addition to PFS, other time-to-event end points include time to
tumor progression (TTP), time to treatment failure (TTF), duration
of response (DOR), and duration of disease control (DDC). Similar
to PFS, the definition of TTP includes the time from randomization
to time of progressive disease; unlike PFS, patients who die without
progression are censored [14]. TTF, defined as the time from
randomization to treatment discontinuation for any reason, including
disease progression, treatment toxicity, patient and/or physician
preference, or death, is not an approvable end point [1] on the basis
that patient and physician preferences are an invalid criterion for
determining efficacy. DOR [15], commonly used in breast cancer and
multiple myeloma and defined as the progressive disease–free interval
after the date of the first observation of response to the date of
progressive disease, only applies to that subset of patients with partial
responses. DDC, a close cousin of PFS2, will be discussed at length
later in this review (Table 1).
The practice of permanently switching therapies at progression,
which defines PFS, implies that each dividing line of therapy, first
line, second line, third line, and so on, constitutes an independent
Table 1. Clinical End Point Key Concepts Defined
Concept Abbreviation Definition
Progression-free survival PFS “The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease that may or may not shrink but
it’s increase in size does not meet the criteria of progressive disease according to the protocol criteria used” [27]
“PFS deferred,” “PFS delayed,” “tandem
PFS,” or “PFS version 2.0”
PFS2 “time from randomisation to objective tumor progression on next-line treatment or death from any cause. In some cases, time on next-line
therapy may be used as proxy for PFS” [8]
Time to tumor progression TTP “The length of time from the date of diagnosis or the start of treatment for a disease until the disease starts to get worse or spread to other parts of
the body.” In the context of pivotal clinical studies, this is the time from randomization to objective tumor progression [27].
Time to treatment failure TTF “TTF is defined as a composite endpoint measuring time from randomization to discontinuation of treatment for any reason, including disease
progression, treatment toxicity, and death.” [28]
Duration of response DOR “Time from documentation of objective tumor response to objective disease progression” [29]
Duration of disease control DDC “DDC is defined as the sum of the PFS of each sequence, except when progressive disease is observed at either reintroduction or second-therapy (DDC =
PFS1 + PFS2 if treatment 2 achieved stabilization or response).” [30]
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of drug efflux, overexpression of antiapoptotic proteins, selective loss
of cell cycle checkpoints, and epigenetic modifications, tumors over
time tend to become increasingly less responsive to subsequent
treatments [16] as they acquire a multidrug-resistant phenotype; in
other words, the coin has a memory. The flip side of this coin is radio-
and chemosensitizing agents, which mitigate or reverse resistance and
enhance the activity of subsequent chemotherapy. Examples, which
include RRx-001 [11], an experimental pan-epigenetic inhibitor in
Phase II clinical trials with radiosensitizing properties [17], or the
DNA hypomethylator decitabine [18], may render tumors hypersus-
ceptible, in other words, “prime” them to respond more robustly, to
salvage therapies.
In light of the recent EMA guidance, cited earlier, entitled Gui-
deline on the evaluation of anticancer medicinal products in man, PFS2
is anticipated to meet regulatory and reimbursement requirements in
Europe and, potentially, the United States as well [19].
This article reviews the clinical use of PFS2 and makes the case for
its potential applicability as a preferred end point to measure the
extended “field of influence” and the “team effort” of individual
agents in a long-term maintenance strategy with resensitizing agents
in particular.
End Points for Maintenance Therapies
Metastatic cancer is, by and large, an incurable disease. The goals of
treatment are to palliate symptoms, improve quality of life, and
potentially prolong survival. The optimal duration of systemic
cytotoxic chemotherapy is unclear even in the setting of a complete
response, partial response, or stable disease given the potential for
continuous treatment to engender resistance, mental fatigue, financial
hardships, and cumulative toxicities. One approach is dose-intensive
therapy where dose modification or treatment delay only occurs in
the context of severe toxicity, whereas another approach is to balance
the efficacy and toxicity of intensive chemotherapy with maintenance
treatment, where the objective is to “hold serve” against the tumor,
that is, not to lose ground and thereby “buy” as much time as possible
with a low–side effect regimen, until clinical progression mandates
the reintroduction of the prior chemotherapy or initiation of a
different one.
The theoretical foundation for maintenance therapy is based on the
Goldie-Coldman hypothesis [20], an influential mathematical model
from the mid-1980s, which supports the use of alternating cycles of
multiple non–cross-resistant treatment modalities—that is, the
rotation of one regimen with another—to reduce toxicities and
forestall the inevitable development of resistance. In metastatic
colorectal cancer, several large randomized clinical trials, OPTI-MOX-2, AIO KRK 0207, and CAIRO-3, have investigated the
feasibility of two types of maintenance therapy, continuation and
switch, as alternatives to distinct lines of continuous treatment.
Continuation maintenance therapy refers to the continuation of one or
more of the initial treatments, whereas switch involves initiation of an
alternate agent.
Clearly, as a discrete “snapshot” tightly framed within the temporal
boundaries of randomization and progression, PFS lacks the depth of
field necessary for a more panoramic view of the multistage
maintenance treatment strategy, making it a nonoptimal end point.
The necessary vision is provided by three alternative end points that
measure a less circumscribed slice of time from the beginning of the
treatment strategy to the end, which were investigated in the
OPTIMOX-2, AIO KRK 0207, and CAIRO-3 trials: DDC, time to
failure of strategy (TFS), and PFS2, respectively. They will be defined
and discussed below.
1. OPTIMOX-2 and DDC
The OPTIMOX-1 study demonstrated the noninferiority of a
regimen with oxaliplatin-free intervals versus continuous
FOLFOX. In the subsequent OPTIMOX-2 trial, oxaliplatin-
free maintenance (5-FU + leucovorin) after FOLFOX chemo-
therapy was compared with chemotherapy discontinuation until
progression, at which point FOLFOX was reintroduced;
however, the actual time of chemotherapy reintroduction varied
[21]. DCC, the primary end point of both OPTIMOX studies,
was nonsignificant and almost identical in both arms (12.9
months vs 11.7 months, in favor of maintenance treatment); the
nonsignificant median OS was 19 versus 26 months [22].DDC
is defined as PFSinitial + PFSreintroduction: the PFS during the initial
phase of treatment (FOLFOX maintenance or FOLFOX
discontinuation) plus the PFS of the reintroduction period
(treatment reintroduction, FOLFOX) provided treatment
reintroduction achieved stabilization or response (Figure 1).
2. AIO KRK 0207 and TFS
In this Phase III trial, a 24-week induction regimen of
fluoropyrimidine/oxaloplatin/bevacizumab was followed with
randomization into one of three arms: 1) observation, that is, no
treatment; 2) doublet fluoropyrimidine plus bevacizumab; or 3)
bevacizumab alone until progression, at which point fluoropyr-
imidine/oxaloplatin/bevacizumab was reintroduced [23]. At a
median follow-up of 27 months, the TFS primary end point was
3.6 months for the no-treatment arm, 6.2 months for the
fluoropyrimidine-plus-bevacizumab arm, and 4.6 months for
the bevacizumab-alone arm, which suggest that active mainte-
nance is superior to none at all even thoughTFS did not correlate
Figure 1. Optimox study and DDC illustrated.
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was observed, leaving open to further question which mainte-
nance strategy is best. TFS is defined as time on maintenance to
either second progression after reinduction or, in case of no
reinduction, after first progression (Figure 2).
3) CAIRO-3 and PFS2
PFS2 is defined by the EMA [8] as “time from randomisation” to
progression on a predetermined next-line therapy postmaintenance.
In the CAIRO-3 study [24], six cycles of induction therapy with
capecitabine and oxaliplatin (XELOX) plus bevacizumab were
followed with randomization to bevacizumab plus capecitabine or
observation, that is, no treatment. On disease progression, therapy
with XELOX plus bevacizumab was restarted until second disease
progression (PFS2), the study’s primary end point (Figure 3). The
median PFS2 of 11.7 months with maintenance treatment versus
8.5 months with observation did not translate to a statistically
significant OS benefit (median OS of 21.6 months with
maintenance therapy vs 18.1 months with observation).
A possible explanation for the weak correlation between these
related end points in the OPTIMOX, AIO KRK 0207, COIN,
and CAIRO-3 trials, which measure overlapping but not identical
concepts, and OS is that the inevitable emergence or (reemergence)Figure 2. AIO KRK 0207 stof resistance during the resensitization phase of the protocol
swamped the small signal of benefit that the DDC, TFS, and PFS2
end points detected for the treatment versus no-treatment arms.
Additional trials are either in progress or in the planning stages with
these surrogate end points to find a maintenance regimen that
confers a clear survival advantage.
Resensitizing Agents
A novel strategy to interrupt or circumvent the vicious cycle of
resistance and enhance susceptibility to next-line treatment, thereby
potentially conferring a survival advantage, involves the introduction
of resensitizing agents. The premise of resensitization is that tumors,
which have developed resistance to one or more therapeutic agents as
a consequence of repeated exposure to these agents, may regain
sensitivity to treatment, that is, become resensitized if the mediator of
the resistance is affected by a subsequent therapeutic agent. Data from
several recent clinical trials with epigenetic inhibitors demonstrate
that despite evidence of intrinsic clinical activity, these agents are
particularly well suited for supporting chemosensitization and
chemoresensitization roles; pretreatment with epigenetic inhibitors
“primes” or preconditions the tumor for response to subsequent
therapy due to the partial abrogation of acquired and intrinsicudy and TFS illustrated.
Figure 3. CAIRO-3 study and PFS2 illustrated.
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colorectal cancer are two of the tumor types where a sensitization/
resensitization strategy either has already been explored or is currently
under investigation.
1. Entinostat and azacitidine
In a Phase I/II clinical trial of a combination of the DNA
demethylator azacitidine and the HDAC inhibitor entinostat in
extensively pretreated recurrent metastatic non–small cell lung
cancer tumor, preconditioning or priming before subsequent
therapies was demonstrated. The median OS of 6.4 months
significantly exceeded that of historical controls [26]. This
favorable clinical outcome was associated with improved
responses to subsequent therapies which included pemetrexed,
docetaxel, erlotinib, anti–programmed cell death protein (PD-1)
monoclonal antibodies, gemcitabine, irinotecan/bevacizumab,
and cisplatin, suggesting that the combination of azacitidine and
entinostat reversed the chemoresistant phenotype and enhanced
sensitivity to multiple subsequent chemotherapeutic agents.Figure 4. ROCKET study design (c2. RRx-001
In colorectal cancer, a randomized Phase II study (ROCKET) of
the approved multikinase inhibitor regorafenib versus RRx-001,
an experimental pan-epigenetic inhibitor and radiosensitizer that
resensitizes or “episensitizes” tumors to formerly effective
chemotherapies, is designed to investigate sequential cytotoxic
rechallenge in irinotecan-refractory third-/fourth-line colorectal
cancer patients after amaintenance/priming periodwithRRx-001.
Per protocol, irinotecan-based therapy is restarted on both the
regorafenib and the RRx-001 arms, if clinically appropriate
(Figure 4). In a 25-patient Phase I trial, RRx-001 demonstrated
evidence of single-agent activity with a PFS that would have led to
underprediction of OS, which was 8.2 months, based on the
prolonged survival of 5/5 patients who were rechallenged with
formerly effective chemotherapies (EpicentRx unpublished data).
To date, in the Phase II trial, 7 of 10 evaluable RRx-001 patients
have been successfully rechallenged with irinotecan-based therapies
after completion of the first priming phase of the study, leading to alinical end point OS) illustrated.
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prolonged stabilization of disease (N4 months); and, in two cases, a
Positron Emission Tomography (PET) partial response. In contrast to
the RRx-001–treated arm, the regorafenib patients have been too
debilitated to start irinotecan chemotherapy. The primary hypothesis
is that the successful reintroduction of previously effective therapies
will significantly improve long-term OS rates compared with the
regorafenib control arm. In anticipation of a Phase III trial, PFS2 is
under consideration as a primary surrogate for OS.
Conclusion
Before Newton discovered gravity, the movement of everyday objects
was explainable in terms of local or contact forces that arose through
physical interaction like the collision of billiard balls in a game of
pool. Gravity, however, was a different matter (no pun intended)
altogether: not a contact force but an intangible one exerted between
objects in space and invisible to the naked eye except through the
prism of advanced mathematics. In the 1850s, Faraday postulated a
force field to explain electromagnetism, envisioning lines of force
similar to the pattern of iron fillings sprinkled around the poles of a
bar magnet, which not only provided an a posteriori mechanism to
understand the action-at-a-distance effects of gravity but also
indirectly helped to make Einstein’s later E = mc2 epiphany possible.
Just as action-at-a-distance was initially hard to accept in physics, it
is similarly unintuitive in oncology that the sequencing of two
temporally separated therapies might affect and be affected by each
other. The potential for drug–drug interaction makes sense in the
context of concomitant exposure. However, it is not a priori obvious
that the effects of separate lines of therapy may spill over into
subsequent treatment lines, influencing the response of the tumor
either positively (in the case of sensitizers) or negatively (in the case of
resistance inducers). This mutual and reciprocal influence isFigure 5. Action-at-a-distance illustrated. Clinical treatments may exe
affected by the treatment administered before and/or afterwards. The
magnetic field pattern.analogous to the above-mentioned action-at-a-distance forces in
physics like gravity, electricity, and magnetism, which are able to exert
a “field of influence” or a “force field.” In oncology, the action-at-a-
distance force field impacts the success or failure of long-term
maintenance strategies, where the induction phase may have a strong
influence on the maintenance phase and vice versa. The problem with
the currently used parameter of PFS is that, unlike the DDC, TFS,
and PFS2 end points, it does not measure or capture the strength of
the “field of influence” on sequential therapies (Figure 5).
PFS2 is a preferred end point for the following reasons: First and
foremost, it is a validated surrogate end point for OS with the EMA,
whereas DDC and TFS are not validated. Second, PFS, an intermediate
end point that shares the same name and initials, is a well-known,
well-understood surrogate for OS, which may lower the barrier to
acceptance of PFS2. Third, according to a 2014 abstract entitledTime to
Second Objective Disease Progression (PFS2): An Emerging Clinical Trial
Endpoint with Regulatory and Reimbursement Implications [19], several
Phase II and III clinical trials in multiple tumor types including breast,
prostate, head and neck, colorectal, pancreatic, non–small cell lung
cancer, andmultiple myeloma are investigating PFS2 as a secondary end
point, which may lead to increased reliance on it in the future.
Finally, just as clinical observations of pseudoprogression that were
not captured by the World Health Organization (WHO) or Response
Evaluation Criteria in Solid Tumors (RECIST) criteria in immuno-
therapy trials led to the adoption of novel immune-related response
criteria, it is anticipated that the unprecedented pattern of
chemosensitization and resensitization observed with epigenetic
agents will require a similar shift from end points such as PFS to
“field of influence”measures like PFS2 that encompass the interactive
dynamic between sequential lines of therapy.
In conclusion, Albert Einstein defined insanity as “doing the same
thing over and over again and expecting different results.” By thatrt “fields of influence” where sequential treatments are potentially
concept of a clinical “field of influence” is compared with the basic
722 PFS2: Measure of Therapeutic Action-At-A-Distance Oronsky et al. Neoplasia Vol. 17, No. 9, 2015same incontrovertible logic, it is time to rethink the automatic
impulse to choose the primary end points of least resistance, PFS and
OS, and potentially explore PFS2 as a surrogate for OS especially in
the context of maintenance trials with epigenetic agents.
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